Curriculum Vitae

Allergenic Products Advisory Committee

Marsha Wills-Karp, Ph.D.

PERSONAL DATA

Office: Division of Immunobiology
Department of Pediatrics
Cincinnati Children’s Hospital Medical Center
3333 Burnet Avenue , MLC 7038
Cincinnati , OH 45229-3039
Ph:-----------------------
Fax: ---------------------
E-mail: m.wills-karp@chmcc.org

Home:
---------------------------
--------------------------

---------------------------------

-------------------------------

--------------------------------

EDUCATION AND TRAINING

B.S., M.S. in Biology	----, ----	Southwest Texas State University, San Marcos, Texas. Minor: Biochemistry
Ph.D. in Physiology	----	University of California, Santa Barbara, California
Postdoctoral Fellow	1986-1987	Yale University, New Haven, Connecticut
Postdoctoral Fellow	1987-1989	Johns Hopkins University, Baltimore, Maryland

PROFESSIONAL EXPERIENCE

2000-present	Professor of Pediatrics, Director, Division of Immunobiology, Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
1996-2000	Associate Professor, Johns Hopkins University, Baltimore MD
1990-1996	Assistant Professor, Johns Hopkins University, Baltimore MD
1989-1990	Research Associate, Johns Hopkins University, Baltimore MD

HONORS AND AWARDS

MEMBERSHIPS: SOCIETIES AND ORGANIZATIONS

CONSULTANT

EDITORIAL ACTIVITIES

GRANT REVIEW COMMITTEES

ACADEMIC SERVICE

**Division and/or Department / University**
1990-present	Participant in Multidisciplinary Training Program in Lung Diseases, Johns Hopkins University, Baltimore, Maryland
1991-1993	Coordinator of Joint Research Seminar for Participants of Pulmonary Training Grant, Johns Hopkins University, Baltimore, Maryland
1992-1993	Elected Member of Faculty Senate of the School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland
1992-1995	Committee on Educational Programs - Environmental Health Sciences, Johns Hopkins University, Baltimore, Maryland
1992-present	Graduate Program and Curriculum Committee - Division of Physiology, Johns Hopkins University, Baltimore, Maryland
1994-1998	Member and Vice-Chairman of School of Hygiene and Public Health Animal Use and Care Committee, Johns Hopkins University, Baltimore, Maryland
2000	Chair, Subcommittee on Faculty Affairs for the Strategic Plan of the School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland
2001	Search Committee for Pulmonary Division Chair, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
2002	Advisory Committee Environmental Health Science, Grant Division of General Pediatrics, P30 Grant
2002	Member, Animal Planning Committee, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

**National**
1993 - present	American Thoracic Society - Member of Program Committee for Annual National Meeting
2001	ATS Education Committee, 2001
2002	ATS Women’s Mentoring Program

TEACHING

**Classroom Instruction**
1978-1980	Teaching Assistant, Laboratory Courses including Cell Physiology, Human Physiology, Plant Physiology, Southwest Texas State University, San Marcos, Texas
1981-1982	Assistant Instructor, Introduction to Biological Sciences, Southwest Texas State University, San Marcos, Texas
1987-1991	Lecturer, Synapses and Receptors in a Physiology Series, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, Maryland
1990-2000	Lecturer, Muscle, Human Physiology Course, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore Maryland
1991- 2000	Lecturer, Sensory Systems and Signal Transduction in Fundamentals of Physiology, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, Maryland
1993-2000	Lecturer, Sensory Systems and Muscle Physiology, Homewood Campus, Johns Hopkins University, Baltimore, Maryland
1994-1998	Lecturer, Sensory Systems and Muscle Physiology, Summer Institute, Johns Hopkins University, Baltimore, Maryland
1995-2000	Course Director: Fundamentals of Human Physiology, Montgomery County, Maryland.
1995-2000	Lecturer, "Air Pollutants" in Immunotoxicology Course, Johns Hopkins University, Baltimore, Maryland
1996-2000	Lecturer, "Allergy" in Immunology Course, Johns Hopkins University, Baltimore, Maryland
1998-2000	Lecturer, "Asthma and Allergy", Uniformed Services University of Health Sciences, Bethesda, Maryland
2001	Lecturer, "Immunology of Disease", University of Cincinnati College of Medicine, Cincinnati, Ohio

Graduate and Post-Graduate Training

Advisees

------------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------------------------

RESEARCH GRANT PARTICIPATION

Research Projects Ongoing or Completed During the Last 3 Years:

Current

Asthma Positional Candidate Genes in Mice and Humans. September 29, 2000-August 31, 2005. NIH/NHLBI. Principal Investigator: Marsha Wills-Karp. Annual Direct Costs: $350,000
Objective: To determine positional candidate genes for asthma.

Positional Candidate Genes for Airway Responsiveness. August 5, 2000-July 31, 2005. NIH/NHLBI. Principal Investigator: Susan Ewart. Annual direct costs: $71,809
Objective: To determine the positional candidate genes for airway responsiveness.

Mechanisms: IL-13-Induced Mucus Hypersecretion in Asthma. April 1, 2003-March 31, 2007. NIH/NHLBI. Principal Investigator: Marsha Wills-Karp. Annual Direct Costs: $250,000
Objective: Overall goal of the proposal is to define the molecular mechanisms underlying IL-13-induced goblet cell metaplasia (GCM).

Immune Phenotypes in Children with Atism Spectrum Disorder. June 1, 2003-May 30, 2005. Cure Autism Now Foundation. Principal Investigator: Cynthia Molloy. Annual Direct Costs: $------
Objective:This pilot project is a case control study designed to compare immune phenotypes, as measured by peripheral blood cytokines, and a history of atopy or familial autoimmunity between children with ASD and controls.

Role of Inflammatory Cytokines in the Allergic Response. July 1, 2003-June 30, 2008. NIH. Principal Investigator: Fred Finkelman. Annual Direct Costs: $27,831
Objective:The studies involved in this proposal will test three related hypotheses that attempt to explain how and why inhalation of some, but not all, antigens stimulates an allergic response.

Biology of IL-13 Receptor Alpha 2. January 1, 2004-December 31, 2008. NIH. Principal Investigator: Gurjit Khurana Hershey. Annual Direct Costs: $1,125,000
Objective:The major goals of this project are to study the biology of the IL-13R a2 using in vivo and in vitro methods and to elucidate the mechanisms underlying its biologic effects.

Mechanism of Mucus Hypersecretion in Cystic Fibrosis. September 1, 2002-August 31, 2005. Cystic Fibrosis Foundation RDP. Principal Investigator: Jeffrey Whitsett. Annual Direct Costs: $-------

Mechanisms of Particulate Matter-induced Allergic Asthma. November 1, 2003-October 31, 2008. Principal Investigator: Peyton Eggleston. Direct Costs: $-------

Interleukin-13 in Experimental Asthma. April 1, 2004-March 31, 2009. Principal Investigator: Marsha Wills-Karp. Direct Costs: $-------------

Complement in Allergic asthma: The Role of C3a and C5a, July 1, 2004-June 30, 2009. Principal Investigator: Joerg Koehl. Direct Costs: $------------

Role of Cockroach Proteases in Airway Inflammation, December 1, 2004-November 30, 2009. Principal Investigator: Kristen Page. Direct Costs: $-------------

Pending

------------------------------------------------------------------------------------------------------------------------------------
------------------------.

Previous

Applied Genomics in Cardiopulmonary Disease. November 1, 2000-October 31, 2004. NIH/NHLBI. Principal Investigator: Joe Garcia. Annual Direct Costs: $87,838
Objective: Identification of genes underlying tissue remodeling in cardiopulmonary diseases.

The Role of Infant Feeding in Childhood Allergy. July 1, 2003-June 30, 2004. Translational Research Trials, Cincinnati Children's Hospital Medical Center. Principal Investigator: Ardythe L. Morrow. Annual Direct Costs: $----------
Objective: The overall goal is to determine whether allergic mothers convey increased risk of alergy to their infants by breastfeeding and the biologic mechanism(s) by which that increased risk might occur.

Regulatory Role of Virus-specific CD8-T Lymphocytes on Allergic Airway Inflammation. July 1, 1997-August 31, 2004. NIH. Principal Investigator: Marsha Wills-Karp. Annual Direct Costs: $150,000

Mechanism of Inflammation-induced Airway Hyperreactivity. July 1, 1999-June 30, 2004. Program Project Grant, NIH/NHLBI. Principal Investigator: Wayne Mitzner. Total Annual Annual Direct costs, $162,399
Objective: To determine the mechanisms by which inflammation alters airway responsiveness.

Center for Childhood Asthma in the Urban Environment. August 1, 1998-July 31, 2003. NIEHS/EPA, Center for Childhood Health. Principal Investigator: Peyton Eggleston. Annual Direct costs: $909,976 Total Direct costs: $5,000,000
Objective: To examine how exposures to environmental pollutants and allergens may relate to airway inflammation and respiratory morbidity in children living with asthma in the inner city of Baltimore.

Regulatory role of virus-specific CD8+ T lymphocytes on allergic airway inflammation. July 1, 1998-August 31, 2003. Principal Investigator: Marsha Wills-Karp. Direct Costs: $------------

Dysregulation of IL-12 in Allergic Inflammation. July 1, 1997-June 30, 2002. NIH/NHLBI. Principal Investigator: Marsha Wills-Karp, Ph.D. Annual Direct Costs $148,860
Objective: The major goal of this project is to determine the role of IL-12 in the development of allergen-induced airway hyperresponsiveness.

Industry study agreement. February 12, 2001-February 12, 2002.

Dynavax Technologies. Principal Investigator: Marsha Wills-Karp. Annual Direct Costs: $-----

Genetics of Allergic Asthma. April 1, 1997-December 31, 1999. Roche Bioscience. Principal Investigator: Marsha Wills-Karp, Ph.D. Annual Direct Costs: $-----------
Objective: The goal of this project was to determine genes important in susceptibility to allergic asthma.

Susceptibility to Airborne Allergen-induced Airway Hyperreactivity. January 1, 1995-December 31, 1997. Center for Indoor Air Research. Principal Investigator: Marsha Wills-Karp, Ph.D. Direct costs of entire project: $-----------
Objective: To determine the immunopathogenic mechanisms involved in the development of allergic asthma.

Role of Epithelium-Derived Cytokines in Oxidant-induced Inflammation. February 1, 1994-January 31, 1996. CAAT. Principal Investigator: Marsha Wills-Karp, Ph.D. Direct costs of entire project: $----------
Objective: To determine the role of epithelial cells in ozone-induced inflammation.

G Proteins and Age-related Changes in Airway Reactivity. July 1, 1989-June 30, 1994; NHLBI. Principal Investigator: Marsha Wills-Karp, Ph.D. Direct costs of entire project: $349,204
Objective: The goal of this proposal is to characterize the intracellular events initiated by muscarinic receptor occupation which lead to contraction of airway smooth muscle and to determine how these processes are altered during aging.

Effects of Ozone on Lymphocyte Function in a Genetic Mouse Model of Susceptibility. October 1, 1991-August 31, 1992; NIEHS – Pilot Project. Grant funded by the Environmental Health Sciences Center Grant, NIEHS ESO 3819-06. Principal Investigator: Marsha Wills-Karp, Ph.D. Direct costs of project: $7,909
Objective: The purpose of this proposal was to determine if lymphocyte function correlates with susceptibility to ozone in two inbred strains of mice, and if so, to begin determining the mechanism of ozone-induced alterations in T-cell function by comparing the T-cell function in the two strains.

Faculty Development Award, January 1, 1995-December 31, 1995.
Direct costs: $-------------
Objective: To determine the inheritance pattern of allergic asthma in mice.

PUBLICATIONS

Koke, J. R., W. Wylie, and M. A. Wills.Sensitivity of flavoprotein fluorescence to oxidative state in single isolated heart cells. Cytobios 32:139-145, 1981.

Koke, J. R., M. A. Wills, and N. Bittar. Contractile activity and oxidative metabolism in single adult myocytes during normoxia and hypoxia. Cytobios 35:149-156, 1982.

Bunnell, D. E., J. A. Agnew, S. M. Horvath, L. Jopson, and M. Wills. Passive body heating and sleep: influence of proximity to sleep. Sleep 11:210-219, 1988.

Wills, M. A. and J. S. Douglas. Functional responses in bovine trachea to cholinergic agonists during aging. Br. J. Pharm. 93:918-924, 1988.

Baumgartner, R. A., M. Wills-Karp, M. J. Kaurman, M. Munakata, and C. Hirshman. Serotonin induces constriction and relaxation of the guinea pig airway. J. Pharmacol. Exp. Ther. 255:165-173, 1990.

Fryer, A. D. and M. Wills-Karp. Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. J. Appl. Physiol. 71:2255-2261, 1991.

Wills-Karp, M. A. Effects of age on muscarinic agonist-induced contraction and IP accumulation in airway smooth muscle. Life Sciences 49:1039-1045, 1991.

Wills-Karp, M., Y. Uchida, J. Y. Lee, J. Jinot, A. Hirata, and F. Hirata. Organ culture with proinflammatory cytokines reproduces impairment of the beta-adrenoceptor-mediated relaxation in tracheas of a guinea pig antigen model. Am. J. Respir. Cell Mol. Biol. 8:153-159, 1993.

Wills-Karp, M. and M. I. Gilmour. Increased cholinergic antagonism underlies impaired beta-adrenergic response in ovalbumin-sensitized guinea pigs. J. Appl. Physiol. 74:2729-2735, 1993.

Wills-Karp, M. Age-related changes in pulmonary muscarinic receptor binding properties. Am. J. Physiol. 265: (Lung Cell. Mol. Physiol. 9):L103-L109, 1993.

Gavett, S. H. and M. Wills-Karp. Elevated lung G-protein levels and muscarinic receptor affinity in a mouse model of airway hyperreactivity. Am. J. Physiol 265: (Lung Cell Mol. Physiol.9):L493-L500, 1993.

Gavett, S. H., X. Chen, F. Finkelman, and M. Wills-Karp. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am. J. Respir. Cell. Mol. Biol. 10:587-593, 1994.

Wills-Karp, M. Effect of aging upon airways smooth muscle reactivity. In: Airways Smooth Muscle: Development, and Regulation of Contractility. D. Raeburn and M. A. Giembycz, Birkhauser Verlag, Basel. p. 185-218, 1994.

Chen, X., S. H. Gavett, and M. Wills-Karp. CD4+ T lymphocyte modulation of ozone-induced murine pulmonary inflammation. Am. J. Respir. Cell Mol. Biol. 12:396-403, 1995.

Gavett, S. H., D. O’Hearn, X. Li, S. Huang, F. D. Finkelman, and M. Wills-Karp. Interleukin-12 inhibits antigen-induced airway hyperreactivity, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 182:1527-1536, 1995.

Wills-Karp, M. , S. H. Gavett, B. Schofield, and F. Finkelman. Role of interleukin-4 in the development of allergic airway inflammation and airway hyperresponsiveness. Adv. Exp. Med. Biol. 409:343-347, 1996.

Wills-Karp, M. , S. H. Gavett, B. Schofield, and F. Finkelman. Role of interleukin-4 in the development of allergic airway inflammation and airway hyperresponsiveness. In: New Horizons in Allergy Immunotherapy. Ed. A. Sehon, et al, Plenum Publishing Corp., New York, p. 343-347, 1996.

Ewart, S., S. Gavett, J. Margolick, and M. Wills-Karp. Cyclosporin A attenuates genetic airway hyperresponsiveness in mice but not through inhibition of CD4+ or CD8+ T cells. Am. J. Respir. Cell Mol. Biol. 14:627-634, 1996.

Foster, W. M., M. Wills-Karp, C. G. Tankersley, X. Chen, and N. C. Paquette. Bloodborne markers in humans during multi-day exposure to ozone. Am. J. Physiol. 81:794-800, 1996.

Li, X., R. K. Chopra, T. Chou, B. H. Schofield, M. Wills-Karp, and S. Huang. Mucosal IFN - g gene transfer inhibits pulmonary allergic responses in mice. J. Immunol. 157:3216-3219, 1996.

Gavett, S. H., D. J. O’Hearn, C. L. Karp, E. A. Patel, B. H. Schofield, F. D. Finkelman, and M. Wills-Karp. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 272 (Lung Cell Mol. Physiol. 16):L253-L261, 1997.

Keane-Myers, A., W. C. Gause, P. S. Linsley, S. Chen, and M. Wills-Karp. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J. Immunol. 158:2042-2049, 1997.

Wills-Karp, M. Smooth muscle as a direct or indirect target accounting for bronchopulmonary hyperresponsiveness. Res. Immunol. 148:59-72, 1997.

Wills-Karp, M. and S. L. Ewart. The genetics of allergen-induced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 156:S89-S96, 1997.

Wills-Karp, M. Interleukin-12 as a target for modulation of the inflammatory response in asthma. Allergy. 53:113-119,1998.

Keane-Myers, A., W. C. Gause, F. D. Finkelman, X. D. Xhou , and M. Wills-Karp. Development of murine allergic asthma is dependent upon B7-2 costimulation. J. Immunol. 160:1036-1043, 1998.

Kuperman, D., B. Schofield, M. Wills-Karp, and M. Grusby. Signal transducer and activator of transcription factor 6 (Stat6)- deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production . J. Exp. Med. 187:939-948, 1998.

Keane-Myers, A., M. Wysocka, G. Trinchieri, and M. Wills-Karp. Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12. J. Immunol. 161:919-926, 1998.

Wills-Karp, M ., J. Luyimbazi, X. Xu, B. Schofield, T. Y. Neben, C. L. Karp, and D. D. Donaldson. Interleukin-13: central mediator of allergic asthma. Science. 282:2258-2261, 1998.

Wills-Karp, M. and L. J. Rosenwasser. Polymorphisms in the IL-13 Promoter. Technical comment. Science. 1999.

Wills-Karp, M. Role of CD4+ T cells in the development of aero-allergen-induced allergic inflammation. In: Asthma: Causes and mechanisms of an epidemic inflammatory disease. Ed. T. Platts-Mills, Lewis Publishers, Boca Raton, FL, p. 87-112, 1999.

Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Ann. Rev. Immunol. 17:255-81, 1999.

Eggleston, P. A., T. J. Buckley, P. N. Breysse, M. Wills-Karp, S. R. Kleeberger, J. J. Jaakkola. The environment and asthma in U. S. inner cities. Environ. Health Perspect. 107(Suppl. 3):439-450, 1999.

Wills-Karp, M. Allergen-induced airway inflammation and airway hyperreactivity in mice. In: In vivo models of inflammation. Birkhauser, Switzerland, ed. Morgan and L. A. Marshall, p. 137-158, 1999.

Mayer, R. J. and M. Wills-Karp. Recent insights into pathogenesis and control of asthma and atopic diseases. Inflammation Research 48:469-70, 1999.

Walters, D. M., M. Wills-Karp, and W. Mitzner. Assessment of cellular profile and lung function with repeated bronchoalveolar lavage in individual mice. Phys. Genomics. 2:29-36, 2000.

Wills-Karp, M. Trophic slime, allergic slime. Am. J. Respir. Cell Mol Biol. 22:637-639, 2000.

Karp, C. L., A. Grupe, E. Schadt, S. L. Ewart, M. Keane-Moore, P. J. Cuomo, J. Kohl, L. Wahl, D. Kuperman, S. Germer, D. Aud, G. Peltz, and M. Wills-Karp. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1:221-226, 2000.

Wills-Karp, M. Murine models of asthma in understanding immune dysregulation in human asthma. Immunopharmacology. 48:263-268, 2000.

Wills-Karp, M. The gene encoding interleukin-13: a susceptibility locus for asthma and related traits. Respir. Res. 1:19-23, 2000.

Ewart, S., D. Kuperman, E. Schadt, C. Tankersley, A. Grupe, D. M. Shubitowski, G. Peltz, and M. Wills-Karp. Quantitative trait loci controlling allergen-induced airway hyperresponsiveness in inbred mice. Am. J. Respir. Cell Mol Biol. 23:537-45, 2000.

Donaldson. D.D., J.A. Elias and M. Wills-Karp. Interleukin-13 Antagonism. Progress in Respiratory Research, New Drugs for Asthma, Allergy and COPD. Ed: T.T. Hansel, P.J. Barnes, Vol 31, p 260-264, 2001.

Keen, J., L. Sholl, M. Wills-Karp, and S. N. Georas. Preferential activation of NFATc correlates with mouse strain susceptibility to allergic responses and IL-4 gene expression. Am. J. Respir. Cell Mol. Biol. 24:58-65, 2001.

Wills-Karp, M. IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol. 107:9-18, 2001.

Karp, C. L. and M. Wills-Karp. Complement and IL-12: Yin and yang. Microbes Infect. 3:109-119, 2001.

Chen, E. S., B. M. Greenlee, M. Wills-Karp, and D. R. Moller. Attenuation of lung inflammation and fibrosis in interferon- g deficient mice following intratracheal bleomycin. Am. J. Respir. Cell Mol. Biol. 24:545-555, 2001.

Donaldson, D. D., J. A. Elias, and M. Wills-Karp. Interleukin-13 antagonism. In: New drugs for asthma, allergy and COPD. Karger. Ed. C.T. Bolliger, 2001.

Wills-Karp, M. , J. Santeliz, and C. L. Karp. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol.. 1:69-76, 2001.

Walters, D. M., P. N. Breysse, and M. Wills-Karp. Ambient urban Baltimore particulate-induced airway hyperresponsiveness and inflammation in mice. Am. J. Respir. Crit. Care. Med. 164:1438-1443, 2001.

Wills-Karp, M. Asthma genetics: not for the TIMid? Nat. Immunol. 2:1095-1096, 2001.

Vehmas, A.K., D.R. Borchelt, D.L. Price, D. McCarthy, M. Wills-Karp, M.J. Peper, G. Rudow, J. Luyinbazi, L.T. Siew, J.C. Troncoso. Beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol 20:713-721, 2001.

Wills-Karp, M. IL-13 Antagonism as a Therapeutic Strategy for the Treatment of Asthma. Lung Biology in Health and Disease Biotherapeutic Approaches to Asthma. Ed. J.M. Agosti, A.L. Sheffer. Vol 167, p 211-223, 2002.

Santeliz, J., G. Van Nest, P. Traquina, E. Larsen, and M. Wills-Karp.Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109(3):455-462, 2002.

Walters, D.M., P.N. Breysse, B. Schofield, and M. Wills-Karp. Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. Am J. Respir. Cell Mol. Biol. 27(4):413-418, 2002.

Polack, F.P., M.N. Teng, P.L. Collins, G.A. Prince, M. Exner, H. Regele, D.D. Lirman, R. Rabold, S.J. Hoffman, S.R. Kleeberger, M. Wills-Karp, R.A. Karron. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196(6):859-865, 2002.

Shubitowski, D.M., M. Wills-Karp and S.L. Ewart. The complement factor 5a receptor gene maps to murine chromosome 7. Cytogenet. Genome Res. 97(1-2):133-135, 2002.

Wills-Karp, M . and M. Chairamonte. Interleukin-13 in asthma. Curr. Opin. Pulm. Med. 9(1):21-27, 2003.

Wills-Karp, M. , C.L. Karp, J. Koehl. Complement factor 5 and asthma. In: Therapeutic Targets in Airway Inflammation. Ed. Eissa, N.T., Huston, D.P. Marcel Dekker, New York, Vol. 177, p 699-713, 2003.

Wills-Karp, M . and G.K.K. Hershey. Immunological Mechanisms of Allergic Disorders. Fundamental Immunology, Fifth Edition. Lippincott-Raven Publishers, Ed. W. Paul, M.D., p. 1439-1479, 2003.

Wills-Karp, M., Y. Belkaid and C.L. Karp. I-Tim-izing the pathways of counter-regulation. Nat Immunol. 4(11):1050-1052, 2003.

Wills-Karp, M. , J. Kohl, and C.L. Karp. Complement factor 5 in asthma. Therapeutic Targets in Airway Inflammation, Vol 177. Marcel Dekker, Inc. Publishers, Ed. N.T. Eissa, D.P. Huston, p. 699-713, 2003.

Wills-Karp, M. Interleukin-13 in asthma pathogenesis. Curr. Allergy Asthma Rep. 4(2):123-131, 2004.

Karp, C.L., L.M. Flick, K.W. Park, S. Softic, T.M. Greer, R. Keledjian, R. Yang, J. Uddin, W.B. Guggino, S.F. Atabani, Y. Belkaid, Y Xu, J.A. Whitsett, F.J. Accurso, M. Wills-Karp, and N.A. Petasis. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5(4):388-392, 2004.

Wills-Karp, M . and S.L. Ewart. Time to draw breath: Asthma-susceptibility genes are identified. Nat. Rev. Genetics 5:376-387, 2004.

Barnes, K.C., L. Caraballo, M. Munoz, A. Zambelli-Weiner, E. Ehrlich, M. Burki, S. Jimenez, R.A. Mathias, M.L. Stockton, P. Deindl, L. Mendoza, G.W. Hershey, R. Nickel, and M. Wills-Karp. A novel promoter polymorphism in the gene encoding complement component 5 receptor 1 on chromosome 19q13.3 is not associated with asthma and atopy in three independent populations. Clin. Exp. Allergy, 34:736-744, 2004.

Hawlisch, H., M. Wills-Karp, C.L. Karp, and J. Köhl. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol. Immunol. 41(2-3):123-131, 2004.

Wills-Karp, M. , D. Brandt, and A.L. Morrow. Understanding the origin of asthma and its relationship to breastfeeding. Advances in Experimental Medicine and Biology, Vol. 554. Kluwer Academic/Plenum Publishers, Ed. L.K. Pickering, A.L. Morrow, G.M. Ruiz-Palacios, and R.J. Schanier, p. 171-191, 2004.

Wills-Karp, M., and C.L.Karp. Biomedicine. Eosinophils in asthma: remodeling a tangled tale. Science, 305:1726-1729, 2004.

Wills-Karp, M., and C.L. Karp. Chitin Checking – Novel insights into asthma. N. Engl. J. Med., 351: 1455-1457, 2004.

Guajardo, J.R., K.W. Schleifer, M. Daines, R.M. Ruddy, B.J. Aronow, M. Wills-Karp, and G.K.K. Hershey. Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma. J. Allergy Clin. Immunol., 115:243-251, 2005.

Zimmerman, N., M.P. Doepker, D.P. Witte, S.M. Pope, P.C. Fulkerson, E.B. Brandt, A. Mishra, N.E. King, N.M. Nikolaidis, M. Wills-Karp, F.D. Finkelman, and M.E. Rothenberg. Expression and regulation of small proline rich protein (SPRR)2 in allergic inflammation. Am. J. Respir. Cell Mol. Biol. 32:428-435, 2005.

Finkelman, F.D., M. Yang, C. Perkins, K. Schleifer, A. Sproles, J. Santeliz, J. Beernstein, M.E. Rothenberg, S.C. Morris, and M. Wills-Karp. Suppressive effect of IL-4 on IL-13-induced genes in mouse lung. J. Immunol. 174:4630-4638, 2005.

-------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------

--------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------

INVITED SEMINARS

**International**
February 1995	"Blockade of Interleukin-4 Receptor Prevents Pulmonary Eosinophilia and Airway Hyperresponsiveness Induced by Antigen Challenge in Mice", International Symposium on Molecular Biology of Allergens and the Atopic Immune Response, Quebec, Canada.
October 1995	"A Murine Model of Susceptibility to Allergen-induced Airway Hyperreactivity", Genetics of Asthma meeting in Worcestershire, England.
November 1995	"Role of Th2 Cytokines in a Murine Model of Allergic Asthma", 2 nd Asian Pacific Congress on Allergology and Clinical Immunology, Taipei, Taiwan.
November 1995	Chair Scientific Session, 2 nd Asian Pacific Congress on Allergology and Clinical Immunology, Taipei, Taiwan.
November 1996	Visiting Professor, "Regulation of Th2 Cytokines in Allergic Inflammation", Vancouver, Canada.
February 1997	"Genetics of Allergic Asthma", Transatlantic Airway Conference, Key Biscayne, Florida.
March 1997	"IL-12 in Allergic Inflammation", 4 th International Congress on the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches, Munich, Germany.
March 1997	"Costimulatory Molecules in Allergic Inflammation", Pasteur Institute, Paris, France.
September 1997	"Immunoregulation in Childhood Asthma", Great Lakes Lung Conference, Ontario, Canada.
September 1997	"Pathogenesis of Allergic Asthma", Queens College, Kingston, Canada.
December 1998	Chair Scientific Session, "Animal Models of Asthma", World Asthma Meeting, Barcelona, Spain.
December 1999	Presenter, 7 th Annual Congress of the British Society for Immunology, London, United Kingdom.
December 1999	Presenter, 1 st International Conference on Immunopharmacology of Bronchial Asthma, Taipei, Taiwan.
January 2000	Presenter, Transatlantic Airway Conference, Lucerne, Switzerland.
September 2000	Presenter, "From the Laboratory to the Clinic", Oxford, England.
January 2001	Presenter, Pasteur Institute, Paris, France.
January 2001	Participant and US Delegate, US/ Taiwan Workshop on Childhood Asthma, Taipei, Taiwan.
December 2001	Presenter, British Society for Immunology, London, England.
August 2002	Presenter, Merck Frosst, Montreal, Quebec, Canada.
October 2002	Presenter, 11 th International Conference of the International Society for Research in Human Milk and Lactation, Mexico City, Mexico.
September 2002	Co-Chair, "Asthma: Animal Models", European Respiratory Society Annual Congress 2002, Stockholm, Sweden.
September 2002	Co-Chair, "good Hygiene and Air Pollution: Synergy or Conflict in Asthma?" European Respiratory Society Annual Congress 2002, Stockholm, Sweden.
September 2002	Presenter, "Molecular basis for Th1 and Th2 imbalance in asthma", European Respiratory Society Annual Congress 2002, Stockholm, Sweden.
November 2002	Presenter, 1 st Kyushu International Allergy Symposium, Fukuoka, Japan
November 2002	Presenter, 18 th International Congress of Clinical Chemistry and Laboratory Medicine, Kyoto, Japan.
November 2002	Presenter, Kyoto University, Kyoto, Japan.
November 2002	Presenter, Fukushima Medical University, Fukushima, Japan.

**National** (Does not include seminars within my department)
1989	"Effects of Age on Muscarinic Receptors in Guinea Pig Lung", Yale University, New Haven, Connecticut.
1991	"Ozone-induced Suppression of Lymphocyte Proliferation", Respiratory Colloquium, University of North Carolina, Chapel Hill, North Carolina.
1991	"Beta -adrenergic Receptors in Lung", Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland.
1992	"Mediators in Bronchial Hyperreactivity", Eudowood Neonatal Pulmonary Division, Johns Hopkins University, Baltimore, Maryland.
1993	"Mechanisms of Airway Hyperreactivity", Department of Anesthesiology, Johns Hopkins University, Baltimore, Maryland.
1993	"Elevated IL-6 mRNA Levels in Mice Genetically Susceptible to Ozone-induced Lung Inflammation", Experimental Biology Meeting, New Orleans, Louisiana.
1993	"The Role of T-lymphocytes in Ozone-induced Inflammation", National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
1993	"Cytokines and Ozone-induced Inflammation", Department of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.
1993	"Cytokines and Ozone-induced Inflammation", Division of Toxicological Sciences, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland.
1994	"IL-6 in Ozone-induced Inflammation", Uniformed Services University of the Health Sciences, Baltimore, Maryland.
1994	"Genetic Mouse Model of Asthma", Millennium Pharmaceuticals, Cambridge, Massachusetts.
1994	"A Murine Model of Asthma", Yale University, New Haven, Connecticut.
1994	"A Murine Model of Asthma", Department of Neurology, Division of Neurovirology, Johns Hopkins University, Baltimore, Maryland.
1994	"A Murine Model of Asthma", Johns Hopkins Allergy and Asthma Center, Baltimore, Maryland.
1994	"A Murine Model of Asthma", Schering-Plough Pharmaceuticals, Inc., Kenilworth, New Jersey.
1994	"Role of Th2 Cytokines in the Pathogenesis of Asthma", Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland.
1994	"Role to T lymphocytes and Cytokines in Antigen-induced Pulmonary Inflammation in Mice", Princeton, New Jersey.
1994	"Role of T lymphocyte-derived Cytokines in the Development of Allergic Responses in Mice", Temple University, Philadelphia, Pennsylvania.
January 1995	"Role of Th2 Cytokines in the Development of Allergic Asthma", Georgetown University, Washington, D.C.
February 1995	Organizer of International Symposium on "Genetics of Asthma", Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland.
March 1995	"Role of Th2 Cytokines in the Development of Antigen-induced Airway Hyperreactivity", Department of Pediatric Immunology, Johns Hopkins University, Baltimore, Maryland.
June 1995	"Role of Th2 Cytokines in Antigen-induced Airway Hyperreactivity", Pediatric Pulmonary Division, Rainbow Babies/Children's Hospital, Cleveland, Ohio.
June 1995	Chair of session on "Airway Hyperreactivity" at National meeting sponsored by the American Thoracic Society and American Academy of Allergy and Immunology, Chicago, Illinois.
July 1995	"Interleukin-12 Inhibits Antigen-induced Airway Hyperresponsiveness, Inflammation, and Th2 Cytokine Production", at Asthma: Theory to Treatment Meeting, Chicago, Illinois.
January 1996	"Role of Th2 Cytokines in Antigen-induced Asthma in Mice", Wistar Institute, Philadelphia, Pennsylvania.
March 1996	"Genetic Mouse Model of Asthma", Maryland Thoracic Society Meeting, Baltimore, Maryland.
May 1996	"Role of Th2 Cytokines in Allergic Asthma", Human Genome Sciences, Gaithersburg, Maryland.
May 1996	Chair of Session on "Animal Models of Asthma", American Thoracic Society Meeting, New Orleans, Louisiana.
May 1996	Invited Speaker in Symposium on Genetics of Asthma, American Thoracic Society Meeting, New Orleans, Louisiana.
July 1996	"Genetic Mouse Model of Asthma", Roche Bioscience, Palo Alto, California.
October 1996	"Th2 Cytokines in Asthma", Smith-Kline Beecham, Philadelphia, Pennsylvania.
October 1996	"IL-12 in Allergic Inflammation", Wistar Institute, Philadelphia, Pennsylvania.
April 1997	"Animal Models of Inflammation and Injury of the Airway", Yale University, New Haven, Connecticut.
June 1997	"Hot Areas in the Field of Asthma", Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts.
July 1997	"Animal Models of Allergic Asthma", Roche Bioscience, Palo Alto, California.
July 1997	"Role of CD4+ T Cells in Aeroallergen-induced Asthma", Center for Indoor Air Research Conference, Jackson Hole, Wyoming.
October 1997	"Role of CD4+ T Cells in the Pathogenesis of Allergic Asthma", Immunology Council Seminar Series, Johns Hopkins University.
November 1997	"Mechanisms of Allergic Asthma", Southwest Texas State University, San Marcos, Texas.
December 1997	"Role of Th2 Cytokines in Allergic Asthma", National Institutes of Health, Bethesda, Maryland.
January 1998	"Pathogenesis of Allergic Asthma", Children’s Hospital, Washington, D.C.
February 1998	"CD4+ T-cell Derived Cytokines in Allergic Asthma", Uniformed Services University of the Health Sciences, Bethesda, Maryland.
March 1998	Breakfast Seminar Series, "Animal Models of Asthma", American Academy of Allergy, Asthma and Immunology National Meeting, Washington, D.C.
March 1998	"A Murine Model of Asthma", Roche Bioscience, Palo Alto, California.
March 1998	"Th2 Cytokines in Allergic Asthma", University of California at San Francisco, San Francisco, California.
April 1998	"Genetics of Allergen-induced Airway Hyperresponsiveness", NIOSH, Morgantown, West Virginia.
October 1998	"Role of CD4+ T cells in Allergic Inflammation", Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
November 1998	"Lessons Learned from Murine Models of Asthma", Roche Bioscience, Palo Alto, California.
January 1999	"Cytokine Regulation of Allergic Inflammation", Keystone Symposium, Lake Tahoe, California.
February 1999	"Interleukin-13 in Allergic Asthma", Academy of Allergy and Immunology Meeting, Orlando, Florida.
February 1999	"Immunoadjuvants", Academy of Allergy and Immunology Meeting, Orlando, Florida.
February 1999	Chair of Session on "Immunoregulation", Academy of Allergy and Immunology Meeting, Orlando, Florida.
March 1999	"Interleukin-13 in Allergic Asthma", Society of Toxicology, New Orleans, Louisiana.
May 1999	"Genetic Loci and Antigen-induced AHR in Mice", at Workshop on the Genetics and Physiology of Airway Hyperresponsiveness, Boston, Massachusetts.
June 1999	"What can we learn from animal models of asthma", in Frontiers in Research and Clinical Management of Asthma and Allergy, Annapolis, Maryland.
June 1999	Scientific Education Network Multi-disciplinary Conference, sponsored by Rhone-Poulenc Rorer Pharmaceuticals, San Diego, California.
July 1999	"Role of CD4+ T cells in the Pathogenesis of Asthma", Harvard, Boston, Massachusetts.
August 1999	Workshop on Pulmonary Immunobiology and Inflammation, NIH, Bethesda, Maryland.
August 1999	Presenter, University of Arizona, Tucson, Arizona.
August 1999	Presenter, Centocor, Malvern, Pennsylvania.
August 1999	Presenter, University of Cincinnati, Cincinnati, Ohio.
September 1999	Workshop on Novel Therapeutics for the Treatment of Asthma, NIH, Bethesda, Maryland.
September 1999	Presenter, "Interleukin-13 in Asthma", Dupont, Delaware.
September 1999	Presenter, Immunology Interest Group, NIH, Bethesda, Maryland.
October 1999	Presenter, Lovelace Respiratory Research Institute Annual Symposium, Santa Fe, New Mexico.
February 2000	Presenter, Washington University, St. Louis, Missouri.
March 2000	Presenter, Academy of Allergy, Asthma and Immunology, San Diego, California.
March 2000	Presenter, University of Maryland at College Park, Department of Chemistry and Biochemistry, College Park, Maryland.
April 2000	Presenter, Keystone Symposia, Snowbird, Utah.
April 2000	Presenter, Tularik, San Francisco, California.
April 2000	Presenter, NIEHS, Research Triangle Park, North Carolina.
May 2000	American Thoracic Society, Toronto, Canada.
May 2000	Presenter, Year 2000 PAS/AAP Joint Meeting, Boston, Massachusetts.
May 2000	NIH Workshop on Stress and Asthma, Bethesda, Maryland.
November 2000	Center for Children in the Urban Environment, San Francisco, California.
January 2001	Presenter, Keystone Symposia, Keystone, Colorado.
February 2001	Invited Speaker, "Utility of Murine Models in the Study of Allergic Phenotypes", International Life Sciences Institute, Health and Environmental Sciences Institute, Washington, D.C.
March 2001	Recipient, John Salvaggio Memorial Lectureship, American Academy of Allergy, Asthma & Immunology, New Orleans, Louisiana.
March 2001	Presenter, "Cytokines and Their Receptors as Targets for Immunotherapy", and "Genetic Basis of Airway Hyperresponsiveness", American Academy of Allergy and Immunology, New Orleans, Louisiana.
May 2001	Presenter, American Thoracic Society Meeting, San Francisco, California.
May 2001	Presenter, Abgenix, "Effects of Anti-IL-13 Antibody Treatment on Allergic Airway Responses", Fremont, California.
July 2001	Co-chair of breakout session: "Genetics of Asthma", The 3rd Triennial World Asthma Meeting, Chicago , Illinois.
January 2002	Presenter, Children’s Health in Urban Environment Centers Annual Meeting, Raleigh, North Carolina.
February 2002	Presenter, PGA Coordinating Committee, Tucson, Arizona.
March 2002	Moderator, AAAAI, "Allergic Inflammation", New York, New York.
March 2002	Presenter, AAAAI, "IL-13 in Asthma", New York, New York.
March 2002	Presenter, AAAAI, "C5 and Asthma", New York, New York.
March 2002	Presenter, Childrens Hospital of Philadelphia, "Role of T Cells in Asthma Pathogenesis", Philadelphia, Pennsylvania.
May 2002	Presenter, ATS, "Utility of Combined Genetic and Genomic Approaches for Identifying Susceptibility Genes", Atlanta, Georgia.
May 2002	Presenter, ATS, "Molecular Effector Mechanisms in Asthma", Atlanta, Georgia.
May 2002	Presenter, ATS, "Genomics of Murine Asthma", Atlanta, Georgia.
May 2002	Presenter, ATS, "Complement Pathway as a Susceptibility Locus for Allergic Asthma", Atlanta, Georgia.
June 2002	Presenter, Trudeau Institute, Saranac Lake, New York.
August 2002	Presenter, Merck Respiratory Consultants Conference, Montreal, Canada
September 2002	Co-Chair, "Asthma: animal models", European Respiratory Society, Stockholm Sweden
September 2002	Presenter, European Respiratory Society, Stockholm Sweden
October 2002	Presenter, "Understanding the origin of allergic disease and its relationship to breastfeeding", 11 th International Conference of the International Society for Research in Human Milk and Lactation, Mexico City, Mexico
October 2002	Speaker, "IL-13 and Asthma", 1 st Kyushu International Allergy Symposium, Fukuoka, Japan
October 2002	Speaker, "Complement and Asthma", Saga Medical School, Saga, Japan
October 2002	Speaker, 18 th International Congress of Clinical Chemistry and Laboratory Medicine, Kyoto, Japan
October 2002	Speaker, Fukushima Medical University, Fukushima, Japan
November 2002	Presenter, "Immunoregulation and asthma: A variety of complementary wheezins", Tri-State Chest Physicians Conference, University of Pittsburgh, Pittsburgh, Pennsylvania.
November 2002	Presenter, "Role of T cells in the pathogenesis of asthma", Pulmonary Grand Rounds, University of Pittsburgh, Pittsburgh, Pennsylvania.
December 2002	Presenter, "IL-4 and IL-13 in Models of Asthma", BSI and BSACI Joint Congress, Harrogate, England.
December 2002	Presenter, "Hygiene Hypothesis", BSI and BSACI Joint Congress, Harrogate, England.
January 2003	Speaker, "Immunoregulation and asthma: A variety of complementary wheezins", The University of Michigan, Ann Arbor, Michigan.
February 2003	Speaker, Respiratory Therapeutics and Inflammation Research Seminar Series, Merck Frosst Center for Therapeutic research, Montreal, Quebec, Canada.
March 2003	Co-Moderator, AAAAI Annual Meeting, Denver, Colorado.
March 2003	Speaker, "Regulation of Mucus Production in the Lower Airway", Breakfast Seminar, AAAAI Annual Meeting, Denver, Colorado
April 2003	Organizer, Keystone Symposia, "Hygiene, Allergy and Asthma", Keystone, Colorado.
April 2003	Speaker, Pulmonary Research Group Spring Meeting, "Role of complement pathways in the pathogenesis of asthma", Malvern, Pennsylvania.
May 2003	Speaker, "Association analysis in animal models", Post Graduate Course, ATS, Seattle, Washington.
May 2003	Speaker, ""Utility of animal models in defining asthma genes", ATS, Seattle, Washington.
May 2003	Speaker, "Allergic inflammation in asthma: Introducing the host response", ATS, Seattle, Washington.
May 2003	Facilitator, "Allergic and Inflammatory Mechanisms of Airways Hyperresponsiveness", ATS, Seattle, Washington.
July 2003	Speaker, "Combined Genetic and Genomic Approaches to Identifying Asthma Susceptibility Genes in Mice", From Genome to Disease: A Symposium of High Throughput Biology, NHLBI, Bethesda, Maryland.
October 2003	Speaker, "Combined Genetic & Genomic Approaches to Identifying Asthma Susceptibility Genes", Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC.
October 2003	Speaker, Pittsburgh International Lung Conference 2003, Nemacolin Woodlands Resort & Spa, University of Pittsburgh, Pittsburgh, PA
December 2003	Speaker, Genomics Seminar Series of the Heflin Center for Human Genetics, University of Alabama at Birmingham, Birmingham, Al.
January 2004	Speaker, "Immunologic and Genetic Mechanisms of Asthma", Biomedical Research Forum, Mayo Clinic, Scottsdale, AZ.
February 2004	Speaker, "Immunogenetics of Asthma", 7 th Annual Meakins-Christie Workshop, Bromont, Quebec, Canada
February 2004	Speaker, "IL-13 in Asthma", Centocor, Inc., Malvern, PA.
March 2004	Moderator, Basic Cutting Edge Late Breaking Abstract Session – Molecular Insights into Clinical Allergy, 60 th Annual Meeting, AAAAI, San Francisco, CA.
March 2004	Speaker, "Measurement of Th1 and Th2 Cytokine Gene Expression Using Microarrays", 60 th Annual Meeting, AAAAI, San Francisco, CA.
March 2004	Discussion Leader, Regulation of Mucus Production in the Lower Airway, 60 th Annual Meeting, AAAAI, San Francisco, CA.
March 2004	Speaker, "Mechanisms of Airway Hyperresponsiveness", 60 th Annual Meeting, AAAAI, San Francisco, CA.
April 2004	Speaker, "Immunoregulation and asthma: A variety of complementary wheezins", Beirne Carter Center for Immunology Research Seminar, University of Virginia, Charlottesville, VA.
April 2004	Moderator, Basic Cutting Edge Late Breading Abstract Session, AAAAI 60 th Annual Meeting, San Francisco, CA
April 2004	Speaker, "The role of cytokines in the induction of airway hyperresponsiveness", AAAAI 60 th Annual Meeting, San Francisco, CA
April 2004	Facilitator, Workshop Mechanisms of Airway Hyperresponsiveness, AAAAI 60 th Annual Meeting, San Francisco , CA
April 2004	Speaker, "Asthma Pathogenesis: Lessons from an Animal Model", AAI EB Annual Meeting, Washington, D.C.
October 2004	Speaker, Merck & Co., Inc., South Burlington, VT.
October 2004	Speaker, Vermont Lung Center, University of Vermont, Burlington, VT.
November 2004	Speaker in Center for Children’s Health in the Urban Environment. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
November 2004	Speaker, in Plenary Session entitled: "Genetics and Genomics of Autoimmunity", 33 rd Autumn Immunology Conference, Chicago, IL.
January 2005	Speaker, Molecular Pathology Seminar Series, Johns Hopkins University School of Medicine, Baltimore, MD.
February 2005	Speaker, 8 th Annual Meakins-Christie Workshop, Quebec, Canada.
March 2005	Speaker, Frontiers in Neonatal and Infant Immunity Symposium, Madrid, Spain.
April 2005	Speaker, Pulmonary and Critical Care Grand Rounds, University of California at Los Angeles, Los Angeles, CA.
May 2005	Speaker, Pediatric Academic Societies 2005 Annual Meeting, Washington, D.C.
May 2005	Speaker, MedImmune, Inc., Gaithersburg, MD.
May 2005	Lead Facilitator, Thematic Poster Session, ATS, San Diego, CA.
May 2005	Chair, Poster Discussion Session, ATS, San Diego, CA.
June 2005	Speaker, V Brazilian Conference on Asthma, Rio de Janeiro, Brazil.
June 2005	Speaker, Hygiene, Infection and Allergy, Sao Paulo, Brazil.